4.81

3.22% -0.16

Telomir Pharmaceuticals Inc (TELO)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$4.97

Offen:

$4.97

24-Stunden-Volumen:

83,534

Relative Volume:

0.53

Marktkapitalisierung:

$143.11M

Einnahmen:

Nettoeinkommen (Verlust:

$-13.08M

KGV:

EPS:

Netto-Cashflow:

1W Leistung:

+5.95%

1M Leistung:

+8.09%

6M Leistung:

+26.25%

1J Leistung:

+0.00%

1-Tages-Spanne:

$4.68

$5.16

1-Wochen-Bereich:

$4.52

$5.34

52-Wochen-Spanne:

$3.11

$20.72

Telomir Pharmaceuticals Inc Stock (TELO) Company Profile

Firmenname

Telomir Pharmaceuticals Inc

Sektor

Healthcare (1173)

Branche

Biotechnology (668)

Telefon

786-396-6723

Adresse

100 SE 2ND ST, MIAMI

Mitarbeiter

Twitter

Nächster Verdiensttermin

2024-11-11

Neueste SEC-Einreichungen

TELO's Discussions on Twitter

Vergleichen Sie TELO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
TELO Telomir Pharmaceuticals Inc	4.81	143.11M	0	-13.08M	0	-0.4416
VRTX Vertex Pharmaceuticals Inc	410.65	105.75B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	716.68	78.76B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	632.04	37.79B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	242.50	31.28B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.77	27.28B	3.30B	-501.07M	1.03B	-2.1146

Telomir Pharmaceuticals Inc Aktie (TELO) Neueste Nachrichten

Dec 26, 2024

Telomir Pharmaceuticals Confirms Copper-Binding Capabilities of Telomir-1 and Expands Pipeline into Wilson’s Disease - Defense World

Dec 26, 2024

Telomir Pharmaceuticals Expands Pipeline, Confirms Copper-Binding Potential of Telomir-1 for Wilson’s Disease - ChemAnalyst

Dec 26, 2024

Dec 23, 2024

Telomir-1 shows promise in copper binding studies - Investing.com

Dec 23, 2024

Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson's Disease - AccessWire

Dec 23, 2024

EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease - Yahoo Finance

Dec 23, 2024

Dec 22, 2024

Telomir Pharmaceuticals appoints new accounting firm - Investing.com India

Dec 22, 2024

Dec 17, 2024

Telomir Pharmaceuticals Raises $1 Million in Premium-Priced Stock Deal, Boosting Age-Reversal Research - Citybuzz

Dec 17, 2024

Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation - Nasdaq

Dec 17, 2024

Dec 16, 2024

Telomir Pharmaceuticals enters into stock purchase agreement - MSN

Dec 16, 2024

Dec 12, 2024

Telomir Pharmaceuticals secures $1 million equity funding - Investing.com

Dec 12, 2024

Telomir Pharmaceuticals Raises $1 Million at $7 per Share in a No-Warrant, Restricted Common Stock Deal, Representing a 20% Premium to Closing Price - AccessWire

Dec 12, 2024

Telomir Pharmaceuticals Secures Premium-Priced Funding After Breakthrough Anti-Aging Drug Results - StockTitan

Dec 12, 2024

Telomir Pharmaceuticals secures $1 million in equity funding By Investing.com - Investing.com Canada

Dec 12, 2024

Dec 11, 2024

Telomir-1 shows promise in diabetes preclinical study By Investing.com - Investing.com Nigeria

Dec 04, 2024

Dec 03, 2024

Unifor And PPWC Target Kruger, Inc. To Begin Western Pattern Bargaining - Barchart

Dec 03, 2024

Stocks In Play: Yukon Metals Corp - Barchart

Dec 03, 2024

Telomir-1 shows promise in diabetes preclinical study - Investing.com India

Dec 03, 2024

Deadline To Apply For A Special Ballot Approaches - Barchart

Dec 03, 2024

Media AdvisoryDeputy Prime Minister's Itinerary For Wednesday, December 4, 2024 - Barchart

Dec 03, 2024

AME ANNOUNCES 2024 AWARD RECIPIENTS - Barchart

Dec 03, 2024

Perimeter Provides Update on Canada Postal Strike and Mailing of the Company's 2024 Annual General Meeting Materials - Barchart

Dec 03, 2024

Ontario Lottery And Gaming CorporationMidDay Lottery Winning NumbersDec. 3, 2024 - Barchart

Dec 03, 2024

Stocks In Play: PyroGenesis Inc. - Barchart

Dec 03, 2024

Fuchs Endothelial Corneal Dystrophy Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | ProQR Therapeutics, Kowa Pharmac, Trefoil Therapeutics, Alcon Inc., Emmecell - Barchart

Dec 03, 2024

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Preclinical Study - newsbreak.com

Dec 03, 2024

Telomir Pharmaceuticals' Shares Rally After Positive Results for Diabetes Treatment - MarketWatch

Dec 03, 2024

Gastroesophageal Adenocarcinoma Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | AskGene Pharma, Inc., Akeso, Weill Medical College, Seagen Inc., Merck, Taiho Pharma - Barchart

Dec 03, 2024

Telomir Pharmaceuticals Achieves Breakthrough in Type 2 Diabetes Treatment with Novel Age-Reversal Drug - Barchart

Dec 03, 2024

Enbridge Inc. Announced 3% Quarterly Dividend Increase For 2025 - Barchart

Dec 03, 2024

Telomir Pharmaceuticals Announces Reversal of Key Type 2 Diabetes Parameters in Groundbreaking Preclinical Study With Telomir-1 - AccessWire

Dec 03, 2024

Dec 02, 2024

Telomir Pharmaceuticals reports breakthrough in diabetes study - Investing.com

Dec 02, 2024

Telomir Pharmaceuticals reports breakthrough in diabetes study By Investing.com - Investing.com Canada

Dec 02, 2024

Nov 29, 2024

Stocks In Play: Southern Energy Corp. - Barchart

Nov 29, 2024

Nov 28, 2024